Mirum Pharmaceuticals, Inc. Operating Income

Quick Answer

Mirum Pharmaceuticals, Inc. reported Operating Income of -$22.14 million for fiscal year 2025.

Mirum Pharmaceuticals, Inc. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$22.14M +74.7%
2024 -$87.61M +19.7%
2023 -$109.15M +16.8%
2022 -$131.22M +24.3%
2021 -$173.41M -66.3%
2020 -$104.30M -90.5%
2019 -$54.74M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 $2.60M +120.5% +152.2%
June 30, 2025 -$4.99M +79.4% +67.1%
March 31, 2025 -$15.18M +42.6% -19.7%
September 30, 2024 -$12.68M +49.6% +47.7%
June 30, 2024 -$24.23M +0.2% +8.4%
March 31, 2024 -$26.47M +2.5% -5.2%
September 30, 2023 -$25.15M +23.5% -3.6%
June 30, 2023 -$24.27M +22.8% +10.6%
  • Mirum Pharmaceuticals, Inc. showed an increase of +74.7% in Operating Income compared to the prior fiscal year.
  • Over the 2019–2025 period, Mirum Pharmaceuticals, Inc.’s operating income has grown by 59.6% (from -$54.74 million to -$22.14 million).
  • The most recent figure is from Mirum Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment